Telotristat ethyl to enhance cytotoxic chemotherapy response in preclinical cholangiocarcinoma models.

331Background: Cholangiocarcinoma (CCA) is the second-most common primary liver cancer after hepatocellular carcinoma. It has a poor prognosis with a 5-year survival rate of 5-15%. The current stan...